公开(公告)号：KR1019960037642A

公开(公告)日：1996-11-19

申请号：KR1019950008823

申请日：1995-04-14

Applicant: 동화약품주식회사

Inventor： 윤성준 ,  정용호 ,  이상욱 ,  이진수 ,  심형수 ,  박용균 ,  이덕근 ,  이원용 ,  우원식 ,  이은방

IPC: C07C233/80

Abstract: 본 발명에 따르면, 하기 일반식(Ⅰ)로 표시되는 2-(4-알콕시벤조일아미노)벤즈아미드 유도체 및 그의 제조방법이 제공된다.

상기 식에서, R
1 은 수소, 탄소수 1-4의 히드록시 치환기를 가질 수 있는 저급 알킬기, 벤질기, 저급 아실기 또는 저급 알콕시카르보닐이고 ; R
2 , R
3 의 하나는 수소 원자, 다른 하나는 치환기를 가질 수도 있는 탄소수 1∼7의 직쇄 또는 분지쇄 알킬기 또는 고리형 알킬기, 또는 벤질기이거나 ; R
2 및 R
3 는 인접한 질소원자와 함께 헤테로고리를 형성할 수 있으며 ; R
4 는 탄소수 1∼4의 직쇄 또는 분지쇄 알킬기 또는 벤질기이다.
본 발명의 화합물은 소염 진통작용이 우수하고 독성과 위장장해 등의 부작용이 거의 없으므로 소염진통제로서 매우 유용하다.

公开(公告)号：KR100420616B1

公开(公告)日：2004-05-17

申请号：KR1019960072384

申请日：1996-12-26

Applicant: 동화약품주식회사

Inventor： 윤성준 ,  정용호 ,  이상욱 ,  심형수 ,  박용균 ,  김종우 ,  허용 ,  노현모 ,  이우길

IPC: C07D401/14

Abstract: PURPOSE: Terephthalic acid amide derivatives are provided, which have improved antiviral activity to hepatitis B virus and no toxicity, so that they can be useful for prevention and treatment of hepatitis B. CONSTITUTION: The terephthalic acid amide derivatives containing substituted phenylpiperazine group represented by formula (1), and pharmaceutically acceptable salts thereof are provided, wherein R1 is hydrogen, halogen, C1-C3 lower alkyl, lower alkoxy or lower acyl, trifluoromethyl, amino or nitro. The method for preparing the terephthalic acid amide derivatives of formula (1) comprises the steps of: (a) reacting a compound of formula (2) with a compound of formula (3) to prepare a compound of formula (4); (b) hydrolysis of benzoic acid methylester of formula (4) to prepare a compound of formula (5); and (c) reacting the compound of formula (5) with acid chloride to prepare acid anhydride and reacting the acid anhydride with a compound of formula (6).

公开(公告)号：KR1020030008654A

公开(公告)日：2003-01-29

申请号：KR1020010043490

申请日：2001-07-19

Applicant: 동화약품주식회사 ,  서홍석

Inventor： 이진수 ,  김판수 ,  황연하 ,  유제만 ,  정용호 ,  서홍석 ,  김은주 ,  김도희 ,  박용엽

IPC: A61K31/426

CPC classification number: A61K31/426 ,  Y10S514/878

Abstract: PURPOSE: Provided are 4-((4-thiazolyl)phenoxy)alkoxy-benzamidine derivatives(DW1350 and DW1352) acting as leukotriene-B4 receptor antagonistic action. The compounds exhibit an excellent inhibition effect on a differentiation, formation, fusion process and bone absorption function of osteoclast cells, therefore they can be effectively used as an prophylaxis and treatment of osteoporosis. CONSTITUTION: The agent for prophylaxis and treatment of osteoporosis contains an effective amount of 4-((4-thiazolyl)phenoxy)alkoxy-benzamidine derivative of formula(1) or a salt thereof. In formula, R is H or OH. The agent is excellent in an inhibition of osteoclast cells as compared to any compound such as DW1349 and DW1351 having structural similarity as well as HS-1141 and CGS-25019C and has increased efficacy in increasing the activity of osteoblast cells.

Abstract translation: 目的：提供作为白三烯-B4受体拮抗作用的4 - （（4-噻唑基）苯氧基）烷氧基 - 苄脒衍生物（DW1350和DW1352）。 该化合物对破骨细胞的分化，形成，融合过程和骨吸收功能具有优异的抑制作用，因此可有效用于预防和治疗骨质疏松症。 构成：用于预防和治疗骨质疏松症的药物含有有效量的式（1）的4​​ - （（4-噻唑基）苯氧基）烷氧基 - 苄脒衍生物或其盐。 在式中，R是H或OH。 与具有结构相似性的DW1349和DW1351以及HS-1141和CGS-25019C的化合物相比，该试剂在破骨细胞抑制方面优异，并且在增加成骨细胞活性方面具有增加的功效。

公开(公告)号：KR1020020068148A

公开(公告)日：2002-08-27

申请号：KR1020010008424

申请日：2001-02-20

Applicant: 동화약품주식회사

Inventor： 황순봉 ,  정용호 ,  유제만 ,  이경재 ,  정숙희 ,  성승규

IPC: C12N15/866

CPC classification number: C12N15/866 ,  C07K1/22 ,  C07K14/005 ,  C07K2319/00 ,  C12N5/0601 ,  C12N2730/10134 ,  C12N2760/10134

Abstract: PURPOSE: Provided is a divalent vaccine against hepatitis B and hepatitis D and a method for preparing it in high yield, thereby preventing hepatitis B and hepatitis D simultaneously. CONSTITUTION: Baculovirus transition vector, pVLHBs(WT)-HDs, contains HBV surface antigen coding gene having 158-836 nt region of SEQ ID NO:1 and HDV delta antigen coding gene having 1601-1016 nt region of SEQ ID NO:7. Recombinant baculovirus is prepared by transfection with the baculovirus transition vector. The divalent vaccine is expressed in a transfected insect cells by recombinant baculovirus.

Abstract translation: 目的：提供一种针对乙型肝炎和丙型肝炎的二价疫苗及其高产率制备方法，从而同时预防乙肝和丙型肝炎。 构成：杆状病毒转移载体pVLHB（WT）-HDs含有具有SEQ ID NO：1具有158-836nt区域的HBV表面抗原编码基因和具有SEQ ID NO：7的1601-1016nt区域的HDVδ抗原编码基因。 通过用杆状病毒转染载体转染制备重组杆状病毒。 二价疫苗通过重组杆状病毒在转染的昆虫细胞中表达。

公开(公告)号：KR1020020013988A

公开(公告)日：2002-02-25

申请号：KR1020000046447

申请日：2000-08-10

Applicant: 동화약품주식회사 ,  한국화학연구원

Inventor： 이철해 ,  김봉진 ,  정원장 ,  김재학 ,  정희정 ,  김은정 ,  송신섭 ,  정용호 ,  곽현정 ,  이진수 ,  편도규

IPC: C07D413/14

CPC classification number: C07D413/06 ,  C07D205/08 ,  C07D265/06 ,  C07D265/14 ,  C07D487/04 ,  C07F9/65611 ,  Y02P20/55

Abstract: PURPOSE: Provided is an intermediate, azetidinone compound which is useful in manufacturing beta-methylcarbapenem antibiotics. And its manufacturing method is provided. CONSTITUTION: The intermediate of carbapenem, azetidinone compound, is represented by the formula(1), wherein R is hydrogen or hydroxy protective group, R1 and R2 are individually C1-C15 alkyl, benzyl, represent 5-6 membered cyclic compound to which R1 and R2 are linked, or hetero cyclic group including at least one oxygen or sulfur atom; R3 is lower alkyl group or lower alkylester group; and R4 is benzene, halogen, lower alkyloxy group, or nitro group substituted benzene ring.

Abstract translation: 目的：提供可用于制备β-甲基碳青霉烯类抗生素的中间体氮杂环丁酮化合物。 并提供其制造方法。 构成：碳青霉烯类氮杂环丁酮化合物的中间体由式（1）表示，其中R是氢或羟基保护基，R1和R2分别是C1-C15烷基，苄基，代表5-6元环状化合物，其中R1 或R 2连接，或包含至少一个氧原子或硫原子的杂环基; R3是低级烷基或低级烷基酯基; R4为苯，卤素，低级烷氧基或硝基取代苯环。

公开(公告)号：KR1020010038923A

公开(公告)日：2001-05-15

申请号：KR1019990047103

申请日：1999-10-28

Applicant: 동화약품주식회사 ,  한국화학연구원

Inventor： 이철해 ,  김봉진 ,  정용호 ,  편도규 ,  송지섭 ,  정희정 ,  곽현정 ,  김은정

IPC: C07D213/89

Abstract: PURPOSE: A method for producing alkyl cis-4-amino-3- methoxy-1-piperidine carboxylate hydrochloride is provided, thereby the titled compound having high purity can be easily produced because the further purification steps are not required and the production is performed under the mild conditions. CONSTITUTION: The method for producing alkyl cis-4-amino-3- methoxy-1-piperidine carboxylate hydrochloride represented by formula (I) comprises the steps of: reacting alkyl trans-4-bromo-3- hydroxypiperidine-1-carboxylate of formula (III) with benzoyl isocyanate in organic solvents to produce alkyl trans-4-bromo-3- benzoylaminocarbonyloxy-1-piperidine carboxylate of formula (IV); adding base such as kalium tert-butoxide into the compound of formula (IV) to produce alkyl cis-1-benzoyl-2-oxo- hexahydro-oxazolo(5,4,c) pyridine-5-carboxylate of formula (V); reacting the compound of formula (V) with lithium hydroxide·H2O to produce alkyl cis-2-oxo-hexahydro-oxazolo(5,4-c) pyridine-5-carboxylate of formula (VI); reacting the compound of formula (VI) with triethylamine, di-tert-butoxy dicarbonate, and dimethylaminopyridine to produce cis-1-tert- butoxycarbonyl-5- ethoxycarbonyl-2-oxo- hexahydro- oxazolo(5,4-c) pyridine of formula (VII); reacting the compound of formula (VII) with cesium carbonate to produce alkyl cis-4-tert- butoxycarbonyl amino-3-hydroxy-1-piperidine carboxylate of formula (VIII); adding sodium hydroxide, dimethyl sulfate, and benzyltriethyl ammonium chloride into the compound of formula (VIII) to produce alkyl cis-4-tert-butoxycarbonylamino- 3-methoxy-1-piperidine carboxylate of formula (IX); and adding hydrogen chloride dissolved organic solvent into the compound of formula (IX) to produce alkyl cis-4-amino-3- methoxy-1-piperidine carboxylate hydrochloride of formula (I).

Abstract translation: 目的：制备顺式-4-氨基-3-甲氧基-1-哌啶羧酸烷基酯盐酸盐的方法，由于不需要进一步的纯化步骤，因此可以容易地制备具有高纯度的标题化合物，并且在 温和的条件。 构成：由式（I）表示的顺式-4-氨基-3-甲氧基-1-哌啶羧酸盐酸烷基酯盐酸盐的制备方法包括以下步骤：使反式-4-溴-3-羟基哌啶-1-羧酸烷基酯 （III）与有机溶剂中的苯甲酰异氰酸酯反应以制备式（IV）的反式-4-溴-3-苯甲酰氨基羰基氧基-1-哌啶羧酸烷基酯; 将碱如叔丁醇钾加入到式（IV）化合物中以制备式（V）的顺式-1-苯甲酰基-2-氧代六氢恶唑并（5,4，c）吡啶-5-羧酸烷基酯; 使式（Ⅴ）化合物与氢氧化锂·H 2 O反应生成式（Ⅵ）的烷基顺式-2-氧代 - 六氢 - 恶唑并（5,4-c）吡啶-5-羧酸酯; 使式（VI）化合物与三乙胺，二叔丁氧基二碳酸酯和二甲基氨基吡啶反应，得到顺式-1-叔丁氧基羰基-5-乙氧基羰基-2-氧代六氢 - 恶唑并（5,4-c）吡啶 式（Ⅶ）; 使式（Ⅶ）化合物与碳酸铯反应制得式（Ⅷ）的顺式-4-叔丁氧基羰基氨基-3-羟基-1-哌啶羧酸烷基酯; 向式（Ⅷ）化合物中加入氢氧化钠，硫酸二甲酯和苄基三乙基氯化铵，得到式（Ⅸ）的顺式-4-叔丁氧基羰基氨基-3-甲氧基-1-哌啶羧酸烷基酯; 并向式（IX）化合物中加入氯化氢溶解的有机溶剂，得到式（I）的烷基顺式-4-氨基-3-甲氧基-1-哌啶羧酸盐酸盐。

公开(公告)号：KR1020010029698A

公开(公告)日：2001-04-06

申请号：KR1020000024657

申请日：2000-05-09

Applicant: 동화약품주식회사

Inventor： 윤성준 ,  정용호 ,  이치우 ,  이진수 ,  김남두 ,  진윤호 ,  송완진 ,  김익회 ,  양왕용 ,  최동락 ,  신정한

IPC: C07D403/04

Abstract: PURPOSE: Provided is a method for manufacturing 4-aminomethyl-4-methyl-3-(Z)-alkoxyamino derivative which has antibacterial effects on both gram positive and negative bacteria so that the derivative is useful for medical purposes. And Its pharmaceutically acceptable salt and its solvate are also provided. CONSTITUTION: A method for producing 4-aminomethyl-4-methyl-3-(Z)-alkoxyamino derivative comprises the following steps of: i) reacting the compound of the formula (3) with ketal compound of the formula (2a) in the presence of acid receptor, for 1-24 hours at 0-150 deg.C, preferably from room temperature to 90 deg.C, to manufacture optically active quinoline carboxylic acid derivative of the formula (4); ii) deketalizing the quinoline carboxylic acid derivative to manufacture pyrrolidinone of the formula (5) at from room temperature to 100 deg.C; and iii) reacting the pyrrolidinone with alkoxylamine in the presence of base at 0-90 deg.C. In the formula (1), Q is C-H, C-F, C-CL, or N. Y is H or NH2. R is a C1-C4 linear or branched alkyl, aryl, or benzyl group. * is an optically pure asymmetric carbon.

Abstract translation: 目的：提供对革兰氏阳性细菌和阴性细菌都具有抗菌作用的4-氨基甲基-4-甲基-3-（Z） - 烷氧基氨基衍生物的制备方法，因此该衍生物可用于医疗目的。 还提供其药学上可接受的盐及其溶剂合物。 构成：4-氨基甲基-4-甲基-3-（Z） - 烷氧基氨基衍生物的制备方法包括以下步骤：i）使式（3）的化合物与式（2a）的缩酮化合物反应于 存在酸受体，在0-150℃，优选室温至90℃下进行1-24小时，以制备式（4）的光学活性喹啉羧酸衍生物; ii）将喹啉羧酸衍生物缩酮化，制备式（5）的吡咯烷酮，室温至100℃; 和iii）在0-90℃下，在碱的存在下使吡咯烷酮与烷氧基胺反应。 在式（1）中，Q是C-H，C-F，C-CL或N.Y是H或NH 2。 R是C1-C4直链或支链烷基，芳基或苄基。 *是光学纯的不对称碳。

公开(公告)号：KR1020000020793A

公开(公告)日：2000-04-15

申请号：KR1019980039547

申请日：1998-09-24

Applicant: 주식회사 한국얀센 ,  동화약품주식회사

Inventor： 윤성준 ,  정용호 ,  이치우 ,  오윤석 ,  임재경 ,  김익회 ,  김동석

IPC: C07D211/58

Abstract: PURPOSE: An N-(4-piperidine) benzamide is prepared by the reaction of thioester and is-piperidine amine derivatives which has gastroenteric irritative physiological activities. CONSTITUTION: Carboxylic derivatives and alkyl chloroformate are reacted to give an intermediate(formula 5), and reacted with 2-mercaptobenzimidazole to give the novel active thioester(formula 3). Active thioester and is-piperidine amine derivatives(formula 2) are reacted to give benzamide derivatives(formula 1; R is C1-C6 lower alkyl; L is an alkyl or aryloxyalkyl). Thus, 376 mg of triethyl amine and 280 mg of ethyl chloroformate are drop in 500 mg of 4-amino-5-chloro-2-methoxybenzoic acid and reacted at 0-10°C for 1.5 hours, adding 396 mg of 2-mercaptobenzimidazole at room temperature for 6 hour. A mixed solution of 630 mg of is-4-amino-3-method-1-£3-(4-fluorophenoxy) propyl|piperidine and 1 ml of N,N-dimethyl form amide is drop at room temperature for 5 hours in the reactant to give 963 mg of is-2-method-4-amino-5-chloro-N-£1-£3-(4- fluorophenoxy)propyl|-3-method-4-piperidinyl|benzamide1 hydrate.

Abstract translation: 目的：通过具有胃肠刺激性生理活性的硫酯和异哌啶胺衍生物的反应制备N-（4-哌啶）苯甲酰胺。 组成：羧酸衍生物和氯甲酸烷基酯反应得到中间体（式5），并与2-巯基苯并咪唑反应得到新的活性硫酯（式3）。 使活性硫酯和哌啶胺衍生物（式2）反应得到苯甲酰胺衍生物（式1; R是C 1 -C 6低级烷基; L是烷基或芳氧基烷基）。 因此，将376mg三乙胺和280mg氯甲酸乙酯滴加到500mg 4-氨基-5-氯-2-甲氧基苯甲酸中，并在0-10℃下反应1.5小时，加入396mg 2-巯基苯并咪唑 在室温下放置6小时。 将630mg的is-4-氨基-3-方法1-（3-氟苯氧基）丙基|哌啶和1ml N，N-二甲基甲酰胺的混合溶液在室温下滴加5小时， 反应物得到963mg的is-2-方法-4-氨基-5-氯-N- {3-（4-氟苯氧基）丙基| 3-方法-4-哌啶基|苯甲酰胺1水合物。

公开(公告)号：KR1020000008471A

公开(公告)日：2000-02-07

申请号：KR1019980028294

申请日：1998-07-14

Applicant: 동화약품주식회사

Inventor： 윤성준 ,  정용호 ,  이치우 ,  오윤석 ,  김남두 ,  임재경 ,  진윤호 ,  김익회 ,  김동석

IPC: C07D211/58

Abstract: PURPOSE: A method for preparing N-(4-piperidine)benzamide is provided in which high purity of compound can be obtained in high yield and a side reaction product is easily separated from an object product. CONSTITUTION: A benzamide derivatives of formula I is obtained by reacting an active ester compound of formula II and a piperidine amine compound of formula III. The active ester compound of formula II is obtained by reacting a compound of formula VI and a compound of formula IV and the piperidine amine compound of formula III is obtained by using a ketone compound of formula VII. The compound of formula VI is obtained by reacting a carboxylic acid compound of formula II` and an ethylchloroformate or an isobytylchloroformate of formula V.

Abstract translation: 目的：提供一种制备N-（4-哌啶）苯甲酰胺的方法，其中可以高产率获得高纯度的化合物，并且副反应产物容易与目标产物分离。 构成：式I的苯甲酰胺衍生物通过使式II的活性酯化合物与式III的哌啶胺化合物反应获得。 式Ⅱ的活性酯化合物是通过使式Ⅵ化合物与式Ⅳ化合物反应得到的，通过使用式Ⅶ的酮化合物得到式Ⅲ的哌啶胺化合物。 式VI化合物通过使式II'的羧酸化合物与氯甲酸乙酯或式V的氯代甲酸异丁酯反应而得到。

公开(公告)号：KR1019990076242A

公开(公告)日：1999-10-15

申请号：KR1019980011019

申请日：1998-03-30

Applicant: 한국화학연구원 ,  동화약품주식회사

Inventor： 이철해 ,  이진수 ,  정용호 ,  정희정 ,  김용주 ,  이홍우 ,  허재두

IPC: C07D477/14 ,  C07D205/02 ,  C07D487/04

Abstract: 본 발명은 하기 구조식(I)의 1-베타메틸 카르바페넴 유도체 및 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항균제 조성물에 관한 것이다.

상기 식에서,
R
1 은 수소, C
1-4 의 알킬, C
1-4 의 시클로알킬, 할로겐으로 치환된 C
1-4 의 알킬 또는 할로겐으로 치환된 C
1-4 의 시클로알킬이고,
R
2 는 C
1-4 의 알킬, C
1-4 의 시클로알킬, 카바모일 또는 아세틸이고,
n은 1 내지 3의 정수이다.